ES413279A1 - Pyridine derivatives having hypoglycaemic activity - Google Patents

Pyridine derivatives having hypoglycaemic activity

Info

Publication number
ES413279A1
ES413279A1 ES413279A ES413279A ES413279A1 ES 413279 A1 ES413279 A1 ES 413279A1 ES 413279 A ES413279 A ES 413279A ES 413279 A ES413279 A ES 413279A ES 413279 A1 ES413279 A1 ES 413279A1
Authority
ES
Spain
Prior art keywords
group
formula
alk
carboxylic acid
pyridyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES413279A
Other languages
Spanish (es)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Robapharm AG
Original Assignee
Robapharm AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Robapharm AG filed Critical Robapharm AG
Publication of ES413279A1 publication Critical patent/ES413279A1/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

A procedure for the preparation of biologically active compounds in the treatment of hypoglycemia of the formula (I) or (II) **(See formula)** in whose formulas "Py" represents a substituted or unsubstituted, 2-, 3- or 4-pyridyl N-oxidized or quaternized pyridyl group; "A" represents a group of the formula (IIIA), (IIIB) or (IIIC) **(See formula)** in which "ALK" represents a straight or branched chain alkylene group with 1 to 6 carbon atoms; R1 represents a carboxylic acid group, a group that is converted in the human body to a carboxylic acid group or an acyl group; R2, R3 and R4 each represent hydrogen, a carboxylic acid group, a group that converts in the human body to a carboxylic acid group, an acyl group, a hydroxy group, an alkoxy group, an aralkoxy group, an aryloxy group, a halogen group or an amino group, except that it is not methyl, cyano or methoxycarbonyl when "Py" is 2-pyridyl or 5-ethylpyrid-2-yl and A is - [O-CH2] - and R2, R3 and R4 are hydrogen or halogen; or one of its pharmaceutically acceptable salts, characterized by condensing a compound of the formula (IV) with a compound of the formula (V) (IV) B - (Alk) nOH HO- (Alk) m-Py (V) in which n and m are 0 or 1, provided that n + m is not zero and "ALK" and "Py" have the meaning indicated in relation to formula (I) or (II) and the symbol B represents a group of the formula (IA) or (IIA) **(See formula)** in which R1, R2, R3 and R4 have the indicated meaning in relation to formula (I) or (II). (Machine-translation by Google Translate, not legally binding)
ES413279A 1972-04-04 1973-04-03 Pyridine derivatives having hypoglycaemic activity Expired ES413279A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1528072A GB1437781A (en) 1972-04-04 1972-04-04 Pyridine derivatives having hypoglycaemic activity

Publications (1)

Publication Number Publication Date
ES413279A1 true ES413279A1 (en) 1976-01-01

Family

ID=10056262

Family Applications (1)

Application Number Title Priority Date Filing Date
ES413279A Expired ES413279A1 (en) 1972-04-04 1973-04-03 Pyridine derivatives having hypoglycaemic activity

Country Status (20)

Country Link
JP (1) JPS49100091A (en)
AR (1) AR208269A1 (en)
AT (1) AT339301B (en)
BE (1) BE797715A (en)
BG (1) BG20352A3 (en)
CA (1) CA999868A (en)
CH (1) CH576961A5 (en)
CS (1) CS183689B2 (en)
DD (1) DD106834A5 (en)
DE (1) DE2316881A1 (en)
ES (1) ES413279A1 (en)
FR (1) FR2182933B1 (en)
GB (1) GB1437781A (en)
HU (1) HU165731B (en)
IE (1) IE37412B1 (en)
IL (1) IL41825A (en)
NL (1) NL7304610A (en)
PL (1) PL96043B1 (en)
RO (2) RO63069A (en)
ZA (1) ZA731853B (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4409227A (en) 1979-08-09 1983-10-11 The Dow Chemical Co. 4-(((Heterocyclo)thio)methyl)benzoic acids, esters and amides and their pharmaceutical use
DE69204231T2 (en) * 1991-07-03 1996-01-25 Unilever Nv Chocolate filling containing an anti-greasy additive.
ATE121271T1 (en) * 1991-07-03 1995-05-15 Unilever Nv IMPROVED CHOCOLATE COMPOSITION.
US5453433A (en) * 1994-05-13 1995-09-26 Sterling Winthrop Inc. Thiadiazoles and antipicornaviral compositions
JP2000509373A (en) * 1996-04-19 2000-07-25 ノボ ノルディスク アクティーゼルスカブ Modulators of molecules with phosphotyrosine recognition units
US6043247A (en) * 1996-04-19 2000-03-28 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
US6329372B1 (en) 1998-01-27 2001-12-11 Celltech Therapeutics Limited Phenylalanine derivatives
ATE273273T1 (en) 1998-02-26 2004-08-15 Celltech Therapeutics Ltd PHENYLALANINE DERIVATIVES AS INHIBITORS OF ALPHA4 INTEGRINS
GB9805655D0 (en) 1998-03-16 1998-05-13 Celltech Therapeutics Ltd Chemical compounds
US6521626B1 (en) 1998-03-24 2003-02-18 Celltech R&D Limited Thiocarboxamide derivatives
GB9811159D0 (en) 1998-05-22 1998-07-22 Celltech Therapeutics Ltd Chemical compounds
GB9811969D0 (en) * 1998-06-03 1998-07-29 Celltech Therapeutics Ltd Chemical compounds
GB9812088D0 (en) 1998-06-05 1998-08-05 Celltech Therapeutics Ltd Chemical compounds
GB9814414D0 (en) * 1998-07-03 1998-09-02 Celltech Therapeutics Ltd Chemical compounds
GB9821061D0 (en) 1998-09-28 1998-11-18 Celltech Therapeutics Ltd Chemical compounds
GB9821222D0 (en) 1998-09-30 1998-11-25 Celltech Therapeutics Ltd Chemical compounds
GB9825652D0 (en) 1998-11-23 1999-01-13 Celltech Therapeutics Ltd Chemical compounds
GB9826174D0 (en) 1998-11-30 1999-01-20 Celltech Therapeutics Ltd Chemical compounds
US6518283B1 (en) 1999-05-28 2003-02-11 Celltech R&D Limited Squaric acid derivatives
US6534513B1 (en) 1999-09-29 2003-03-18 Celltech R&D Limited Phenylalkanoic acid derivatives
US6455539B2 (en) 1999-12-23 2002-09-24 Celltech R&D Limited Squaric acid derivates
EP1332132B1 (en) 2000-04-17 2007-10-10 UCB Pharma, S.A. Enamine derivatives as cell adhesion molecules
US6545013B2 (en) 2000-05-30 2003-04-08 Celltech R&D Limited 2,7-naphthyridine derivatives
US6403608B1 (en) 2000-05-30 2002-06-11 Celltech R&D, Ltd. 3-Substituted isoquinolin-1-yl derivatives
AU2001267753A1 (en) 2000-07-07 2002-01-21 Celltech R And D Limited Squaric acid derivatives containing a bicyclic heteroaromatic ring as integrin antagonists
AU2001275724A1 (en) 2000-08-02 2002-02-13 Celltech R&D Limited 3-substituted isoquinolin-1-yl derivatives
KR101009472B1 (en) * 2001-06-12 2011-01-19 웰스테트 테라퓨틱스 코포레이션 Compounds for the Treatment of Metabolic Disorders
GB0405033D0 (en) * 2004-03-05 2004-04-07 Karobio Ab Novel pharmaceutical compositions
TWI490214B (en) * 2008-05-30 2015-07-01 艾德克 上野股份有限公司 Benzene or thiophene derivative and use thereof as vap-1 inhibitor
EP3019034B1 (en) 2013-07-01 2018-10-31 Givaudan SA Organic compounds
WO2016167153A1 (en) * 2015-04-15 2016-10-20 長谷川香料株式会社 Flavor modulator having pyridine derivative or salt thereof as active ingredient
WO2017174879A1 (en) * 2016-04-06 2017-10-12 University Of Oulu Compounds for use in the treatment of cancer

Also Published As

Publication number Publication date
DE2316881A1 (en) 1973-10-11
FR2182933A1 (en) 1973-12-14
CS183689B2 (en) 1978-07-31
IE37412B1 (en) 1977-07-20
NL7304610A (en) 1973-10-08
BG20352A3 (en) 1975-11-05
GB1437781A (en) 1976-06-03
RO63069A (en) 1978-08-15
HU165731B (en) 1974-10-28
IE37412L (en) 1973-10-04
AR208269A1 (en) 1976-12-20
DD106834A5 (en) 1974-07-05
IL41825A0 (en) 1973-05-31
ATA286773A (en) 1977-02-15
PL96043B1 (en) 1977-11-30
JPS49100091A (en) 1974-09-20
IL41825A (en) 1977-03-31
BE797715A (en) 1973-10-03
ZA731853B (en) 1974-01-30
CA999868A (en) 1976-11-16
AT339301B (en) 1977-10-10
RO62274A (en) 1977-12-15
FR2182933B1 (en) 1976-05-14
CH576961A5 (en) 1976-06-30

Similar Documents

Publication Publication Date Title
ES413279A1 (en) Pyridine derivatives having hypoglycaemic activity
KR880001591A (en) Tetrahydro Naphthalene and Phosphorus Derivatives
ES476955A1 (en) Quinazoline derivatives, process for their preparation, pharmaceutical preparations and their preparation.
FR2414039A1 (en) PROSTACYCLINE DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR THERAPEUTIC APPLICATIONS
JPS5412372A (en) Thiazolidine derivative and its preparation
GB1384504A (en) Bridgeheadheterocyclic compounds their production and their medicinal use
FR2354761A1 (en) N-ARYL-ANTHRANILIC ACIDS, THEIR PREPARATION METHODS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAID ANTHRANILIC ACIDS
FR2430418A1 (en) HALOGENOMETHYL DERIVATIVES OF A-AMINO ACIDS, THEIR PREPARATION AND THEIR THERAPEUTIC USES
GB1438265A (en)
DE3773017D1 (en) PREPARATION FOR INJECTION CONTAINING NICORANDIL.
NO811798L (en) NEW SUBSTITUTED 3-PHENOXY-1-ALCOXYCARBONYL-ALKYLAMINOPROPANOLS-2 WITH BETA-RECEPTOR BLOCKING PROPERTIES
IE40068L (en) 1, 4- dihydro -h- isoquinolines
FR2372836A1 (en) PROPIONIC ACID DERIVATIVES, THEIR METHODS OF PREPARATION AND THEIR APPLICATION IN THERAPEUTICS
SE7701187L (en) NEW PIPERAZINE DERIVATIVES AND WAY TO PRODUCE THE SAME
ES475361A1 (en) Pyridine derivative, its preparation and use
ES476266A1 (en) Cyclic diamine n,n'-disubstituted and process for preparing the same
JPS5283380A (en) Synthesis of thiocarbostyril derivatives
GB1391862A (en) Benzodiazepines
FR2390954A1 (en) NEW GUANYLHYDRAZONES, THEIR METHODS OF PREPARATION AND THE MEDICINAL PRODUCTS CONTAINING THEM
JPS5419969A (en) Proline derivative and its preparation
FR2368489A1 (en) CLAVULIN DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR THERAPEUTIC APPLICATION
FI892685A0 (en) Method for the preparation of new cytostatically active anthracycline derivatives
ES433131A1 (en) Derivatives of 1-phenoxy-3-aminopropan-2-ol and processes for their preparation
ES369304A1 (en) IMIDAZO-3H-(4,5-b)-PYRIDINE DERIVATIVES
GB1444879A (en) 3-acylamino-6-amino-3,4-dihydro-2-pyridones and their use as medicaments